G3BP1 and cancer: Knocking-down G3BP1 reduces SG assembly in cancer cells treated with bortezomib (BZM), a proteasome inhibitor used for a range of hematological tumors, potentiating chemotherapeutic-induced cancer cell death (Klein et al., 2020).